{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:34:44Z","timestamp":1753878884589,"version":"3.41.2"},"reference-count":29,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"vor","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Cellular Molecular Medi"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Microtransplantation is a cellular therapy used in acute myeloid leukaemia and myelodysplastic syndromes as a maintenance therapy in patients ineligible for a regular allogeneic stem cell transplantation. We performed a monocentric retrospective study of acute myeloid leukaemia, myelodysplastic syndromes, and chronic myelomonocytic leukaemia patients who underwent microtransplantations at Nice University Hospital. We analysed the evolution of the disease mutational status after microtransplantation. We report 18 patients who underwent microtransplantation courses, with a total of 47 microtransplantations performed between February 2020 and June 2022. We observed long\u2010term remissions even in high\u2010risk patients. Founder mutations persisted throughout the follow\u2010up, whereas it was more variable for other nonfounder mutations, with most of the nonfounder mutations variant allele frequency decreasing over time. Safety data were reassuring; no graft versus host disease was recorded, and cytokine release syndromes were manageable. Relapses or progressions were associated with the emergence or increase of a <jats:italic>TP53<\/jats:italic> mutated clone. Microtransplantation is a promising therapy for patients ineligible for regular allogeneic stem transplantation. Further larger and randomised studies are required to establish its place as a maintenance therapy in myeloid malignancies.<\/jats:p>","DOI":"10.1111\/jcmm.70520","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T23:41:02Z","timestamp":1742946062000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clonal Evolution of Myeloid Malignancies Treated With Microtransplantation: A Single\u2010Centre Experience"],"prefix":"10.1111","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3015-0846","authenticated-orcid":false,"given":"R.","family":"Sammut","sequence":"first","affiliation":[{"name":"D\u00e9partement d'H\u00e9matologie Centre Hospitalier Universitaire de Nice  Nice France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Fenwarth","sequence":"additional","affiliation":[{"name":"Laboratoire d'H\u00e9matologie Centre Hospitalier Universitaire de Lille  France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Pelissier","sequence":"additional","affiliation":[{"name":"Department of Biosystems Science and Engineering ETH Zurich  Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Marceau","sequence":"additional","affiliation":[{"name":"Laboratoire d'H\u00e9matologie Centre Hospitalier Universitaire de Lille  France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Duployez","sequence":"additional","affiliation":[{"name":"Laboratoire d'H\u00e9matologie Centre Hospitalier Universitaire de Lille  France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Benachour","sequence":"additional","affiliation":[{"name":"D\u00e9partement d'H\u00e9matologie Centre Hospitalier Universitaire de Nice  Nice France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Dadone","sequence":"additional","affiliation":[{"name":"Laboratoire Central d'anatomie et de Cytologie Pathologique Centre Hospitalier Universitaire de Nice  Nice France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Cluzeau","sequence":"additional","affiliation":[{"name":"D\u00e9partement d'H\u00e9matologie Centre Hospitalier Universitaire de Nice  Nice France"},{"name":"INSERM U1065, Centre de M\u00e9decine Mol\u00e9culaire M\u00e9diterran\u00e9en Universit\u00e9 Nice Cote d'Azur  Nice France"},{"name":"Universit\u00e9 Cote d'Azur  Nice France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Loschi","sequence":"additional","affiliation":[{"name":"D\u00e9partement d'H\u00e9matologie Centre Hospitalier Universitaire de Nice  Nice France"},{"name":"INSERM U1065, Centre de M\u00e9decine Mol\u00e9culaire M\u00e9diterran\u00e9en Universit\u00e9 Nice Cote d'Azur  Nice France"},{"name":"Universit\u00e9 Cote d'Azur  Nice France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,3,24]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/978\u20100\u2010387\u201078580\u20106_1"},{"issue":"30","key":"e_1_2_12_3_1","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1200\/JCO.20.02724","article-title":"Comparison Between 5\u2010Azacytidine Treatment and Allogeneic Stem\u2010Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study)","volume":"39","author":"Kr\u00f6ger N.","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"26","key":"e_1_2_12_4_1","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission","volume":"383","author":"Wei A. H.","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"13","key":"e_1_2_12_5_1","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1182\/blood-2018-10-879866","article-title":"Azacitidine Maintenance After Intensive Chemotherapy Improves DFS in Older AML Patients","volume":"133","author":"Huls G.","year":"2019","journal-title":"Blood"},{"issue":"14","key":"e_1_2_12_6_1","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1182\/blood.2021013404","article-title":"Oral Azacitidine Prolongs Survival of Patients With AML in Remission Independently of Measurable Residual Disease Status","volume":"139","author":"Roboz G. J.","year":"2022","journal-title":"Blood"},{"issue":"8","key":"e_1_2_12_7_1","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2018-08-869453","article-title":"Midostaurin Added to Chemotherapy and Continued Single\u2010Agent Maintenance Therapy in Acute Myeloid Leukemia With FLT3\u2010ITD","volume":"133","author":"Schlenk R. F.","year":"2019","journal-title":"Blood"},{"issue":"13","key":"e_1_2_12_8_1","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/blood.2020007233","article-title":"Ivosidenib or Enasidenib Combined With Intensive Chemotherapy in Patients With Newly Diagnosed AML: A Phase 1 Study","volume":"137","author":"Stein E. M.","year":"2021","journal-title":"Blood"},{"issue":"13","key":"e_1_2_12_9_1","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1182\/bloodadvances.2020001482","article-title":"Venetoclax and Hypomethylating Agents (HMAs) Induce High Response Rates in MDS, Including Patients After HMA Therapy Failure","volume":"4","author":"Ball B. J.","year":"2020","journal-title":"Blood Advances"},{"issue":"12","key":"e_1_2_12_10_1","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11864-018-0583-4","article-title":"Improving Treatment for Myelodysplastic Syndromes Patients","volume":"19","author":"Montoro J.","year":"2018","journal-title":"Current Treatment Options in Oncology"},{"key":"e_1_2_12_11_1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.628127","article-title":"Decitabine With or Without Micro\u2010Transplantation for the Treatment of Intermediate or High\u2010Risk Myelodysplastic Syndrome: A Chinese Single\u2010Center Retrospective Study of 22 Patients","volume":"11","author":"Li M.","year":"2021","journal-title":"Frontiers in Oncology"},{"issue":"5","key":"e_1_2_12_12_1","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.bbmt.2017.01.085","article-title":"Decitabine Before Low\u2010Dose Cytarabine\u2010Based Chemotherapy Combined With Human Leukocyte Antigen\u2010Mismatched Stem Cell Microtransplantation Improved Outcomes in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia","volume":"23","author":"Zhu Y.","year":"2017","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"6","key":"e_1_2_12_13_1","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/MOH.0000000000000470","article-title":"Microtransplantation: Clinical Applications and Mechanisms","volume":"25","author":"Cai B.","year":"2018","journal-title":"Current Opinion in Hematology"},{"issue":"3","key":"e_1_2_12_14_1","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood-2010-06-288506","article-title":"Infusion of HLA\u2010Mismatched Peripheral Blood Stem Cells Improves the Outcome of Chemotherapy for Acute Myeloid Leukemia in Elderly Patients","volume":"117","author":"Guo M.","year":"2011","journal-title":"Blood"},{"issue":"1","key":"e_1_2_12_15_1","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1001\/jamaoncol.2017.2656","article-title":"HLA\u2010Mismatched Microtransplant in Older Patients Newly Diagnosed With Acute Myeloid Leukemia: Results From the Microtransplantation Interest Group","volume":"4","author":"Guo M.","year":"2018","journal-title":"JAMA Oncology"},{"issue":"4","key":"e_1_2_12_16_1","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and Management of AML in Adults: 2017 ELN Recommendations From an International Expert Panel","volume":"129","author":"D\u00f6hner H.","year":"2017","journal-title":"Blood"},{"issue":"12","key":"e_1_2_12_17_1","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised International Prognostic Scoring System for Myelodysplastic Syndromes","volume":"120","author":"Greenberg P. L.","year":"2012","journal-title":"Blood"},{"issue":"20","key":"e_1_2_12_18_1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 Revision to the World Health Organization Classification of Myeloid Neoplasms and Acute Leukemia","volume":"127","author":"Arber D. A.","year":"2016","journal-title":"Blood"},{"issue":"10","key":"e_1_2_12_19_1","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","article-title":"Integrating Clinical Features and Genetic Lesions in the Risk Assessment of Patients With Chronic Myelomonocytic Leukemia","volume":"128","author":"Elena C.","year":"2016","journal-title":"Blood"},{"issue":"8","key":"e_1_2_12_20_1","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic Cell Transplantation (HCT)\u2010Specific Comorbidity Index: A New Tool for Risk Assessment Before Allogeneic HCT","volume":"106","author":"Sorror M. L.","year":"2005","journal-title":"Blood"},{"issue":"10","key":"e_1_2_12_21_1","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1182\/blood-2018-06-857102","article-title":"Proposals for Revised IWG 2018 Hematological Response Criteria in Patients With MDS Included in Clinical Trials","volume":"133","author":"Platzbecker U.","year":"2019","journal-title":"Blood"},{"issue":"12","key":"e_1_2_12_22_1","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2014-10-607341","article-title":"An International Consortium Proposal of Uniform Response Criteria for Myelodysplastic\/Myeloproliferative Neoplasms (MDS\/MPN) in Adults","volume":"125","author":"Savona M. R.","year":"2015","journal-title":"Blood"},{"issue":"24","key":"e_1_2_12_23_1","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia","volume":"21","author":"Cheson B. D.","year":"2003","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_12_24_1","unstructured":"\u201cCommon Terminology Criteria for Adverse Events (CTCAE) Protocol Development CTEP [Internet].\u201dhttps:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_50."},{"issue":"1","key":"e_1_2_12_25_1","doi-asserted-by":"crossref","first-page":"7244","DOI":"10.1038\/s41467-021-27472-5","article-title":"Clonal Architecture Predicts Clinical Outcomes and Drug Sensitivity in Acute Myeloid Leukemia","volume":"12","author":"Benard B. A.","year":"2021","journal-title":"Nature Communications"},{"issue":"1","key":"e_1_2_12_26_1","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1186\/s12864-016-3195-z","article-title":"Visualizing Tumor Evolution With the Fishplot Package for R","volume":"17","author":"Miller C. A.","year":"2016","journal-title":"BMC Genomics"},{"issue":"7","key":"e_1_2_12_27_1","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1073\/pnas.1324297111","article-title":"Preleukemic Mutations in Human Acute Myeloid Leukemia Affect Epigenetic Regulators and Persist in Remission","volume":"111","author":"Corces\u2010Zimmerman M. R.","year":"2014","journal-title":"National Academy of Sciences of the United States of America"},{"issue":"6","key":"e_1_2_12_28_1","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/ajh.25781","article-title":"Microtransplantation in Older Patients With AML: A Pilot Study of Safety, Efficacy and Immunologic Effects","volume":"95","author":"Sung A. D.","year":"2020","journal-title":"American Journal of Hematology"},{"issue":"26","key":"e_1_2_12_29_1","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1182\/blood-2018-02-832360","article-title":"Prognostic Factors Influencing Survival After Allogeneic Transplantation for AML\/MDS Patients With TP53 Mutations","volume":"131","author":"Ciurea S. O.","year":"2018","journal-title":"Blood"},{"issue":"4","key":"e_1_2_12_30_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e14924","article-title":"Expert Consensus on Microtransplant for Acute Myeloid Leukemia in Elderly Patients\u2014Report From the International Microtransplant Interest Group Ma L","volume":"9","author":"Ai H.","year":"2023","journal-title":"Heliyon"}],"container-title":["Journal of Cellular and Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jcmm.70520","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T05:08:38Z","timestamp":1743397718000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcmm.70520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1111\/jcmm.70520"],"URL":"https:\/\/doi.org\/10.1111\/jcmm.70520","archive":["Portico"],"relation":{},"ISSN":["1582-1838","1582-4934"],"issn-type":[{"type":"print","value":"1582-1838"},{"type":"electronic","value":"1582-4934"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"2024-05-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70520"}}